LY2835219 Abemaciclib Mesylate CDK Inhibitor Cas 1231930-82-7
LY2835219 Abemaciclib Mesylate CDK Inhibitor Cas 1231930-82-7
+ AII PRODUCTS
- Prostaglandins - Custom Synthesis - PARP Inhibitors - PI3K Inhibitors - FAK Inhibitors - AKT Inhibitors - C-Kit Inhibitors - VEGFR Inhibitors - c-Met Inhibitors - CDK Inhibitors - CYP17 Inhibitors - DNA/RNA Inhibitors - mTOR Inhibitors - SRC Inhibitors - Others
Product
|
Size |
Price |
Stock |
Quantity |
|---|---|---|---|
|
Get Quotation Now Add to Cart Bulk Inquiry |
|||
AddThis Sharing Buttons
Share to FacebookFacebookShare to TwitterTwitterShare to PrintPrintShare to EmailEmailShare to PinterestPinterestShare to GmailGmailShare to LinkedInLinkedInShare to Email AppEmail AppShare to TumblrTumblrShare to MoreAddThis
Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.
Chemical Information
|
Product name:LY2835219 abemaciclib mesylate |
Purity:98% min |
|
CAS NO:1231930-82-7 |
Solubility:DMSO25 mg/mL (41.48 mM) |
|
Molecular Formula:C28H36F2N8O3S |
Package:Package according to customer requirements |
|
Molecular Weight:602.699 |
Storage:Store at -20℃ |
Quality control
Remarks
Abemaciclib, also known as LY2835219, is orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. LY2835219 inhibits CDK4 and CDK6 with low nanomolar potency. LY2835219 specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation in early G1. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth.
Related Products
Flavopiridol HCL; Flavopiridol; THZ1; BMS-863233 HCl; Dinaciclib; AZD5438; Seliciclib; Palbociclib Isethionate; PHA-793887; RO-3306; Abemaciclib; JNJ-7706621
References
[1].Ku BM, et al. The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma. Oncotarget. 2016 Mar 22;7(12):14803-13.
[2].Yadav V, et al. The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulati
Get in Touch
Have questions about our products or want to discuss a custom order? Our team is ready to help you.